Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA: EBRT vs CXB Boost in Rectal Adenocarcinoma
NCT02505750Phase 3Active, not recruiting
- Sponsor
- Centre Antoine Lacassagne
- Start
- Jun 2015
- Primary completion
- Jun 2023
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in rectal adenocarcinoma (3 arms), sponsored by Centre Antoine Lacassagne. Primary endpoint: Rate of rectum preservation at 3 years. Started Jun 2015; status: active, not recruiting.
02
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT02505750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505750.